• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Anavex Life Sciences Corp. (Amendment)

    2/13/24 4:58:52 PM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AVXL alert in real time by email
    SC 13G/A 1 tv0288-anavexlifesciencescor.htm SCHEDULE 13G/A anavexlifesciencescorp

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 2)*

    Name of issuer:  Anavex Life Sciences Corp

    Title of Class of Securities:  Common Stock

    CUSIP Number:  032797300

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  032797300

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    136,057

    7.  SOLE DISPOSITIVE POWER

    4,155,886

    8.  SHARED DISPOSITIVE POWER

    204,762

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,360,648

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.31%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Anavex Life Sciences Corp

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    630 5th Avenue, 20th floor
    New York, NY 10111

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    032797300

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $AVXL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVXL

    DatePrice TargetRatingAnalyst
    12/6/2022$16.00 → $11.00Overweight → Neutral
    Cantor Fitzgerald
    6/23/2022$40.00Buy
    Berenberg
    2/2/2022$39.00 → $42.00Buy
    HC Wainwright & Co.
    9/23/2021$35.00Buy
    BTIG Research
    6/28/2021$25.00 → $39.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AVXL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

      NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that its President & Chief Executive Officer, Christopher U. Missling, PhD, will participate at both the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference. Both conferences will take place in New York City (NY

      5/14/25 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

      Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its second quarter of fiscal 2025. "Anavex's portfolio with non-invasive targeted upstream precision compounds continues to advance with special focus on Alzheimer's disease and schizophrenia. We also co

      5/13/25 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

      NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its second fiscal quarter on Tuesday , May 13, 2025. Management will host a conference call on Tuesday, May 13, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strategy. Following managem

      5/6/25 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVXL
    Financials

    Live finance-specific insights

    See more
    • Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

      Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its second quarter of fiscal 2025. "Anavex's portfolio with non-invasive targeted upstream precision compounds continues to advance with special focus on Alzheimer's disease and schizophrenia. We also co

      5/13/25 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

      NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its second fiscal quarter on Tuesday , May 13, 2025. Management will host a conference call on Tuesday, May 13, at 8:30 am ET to review financial results and provide an update on the execution of the Company's growth strategy. Following managem

      5/6/25 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

      Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its first quarter of fiscal 2025. "We are receiving growing support from stakeholders for the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing with potential c

      2/12/25 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVXL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by PFO & Treasurer Boenisch Sandra

      4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

      4/30/25 8:00:38 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President and CEO Missling Christopher U

      4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

      4/30/25 8:00:22 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Donhauser Peter D.O.

      4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

      4/2/25 9:47:21 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVXL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Anavex Life Sciences Corp. (Amendment)

      SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)

      2/13/24 4:58:52 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Anavex Life Sciences Corp. (Amendment)

      SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)

      1/22/24 11:34:51 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Anavex Life Sciences Corp. (Amendment)

      SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)

      2/9/23 11:07:31 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVXL
    Leadership Updates

    Live Leadership Updates

    See more
    • Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

      NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Professor Dr. Audrey Gabelle, MD, PhD, a specialist of predictive, personalized medicine and digital health in Alzheimer' disease and related disorders, to the Anavex Scientific Advisory Board. Dr. Audrey Gabelle is a Professor of Neurology, MD, PhD, Neurologist and

      4/23/25 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Anavex Life Sciences Announces Expansion of Leadership Team

      NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced the addition and appointment of new senior team members with a track record of successfully bringing drugs to market. Reinforcing the Company's commitment to drive value-creation through operational efficiencies and innovation in the industry, Anavex announces n

      5/22/24 7:30:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Anavex Life Sciences investors: Please contact the Portnoy Law Firm to recover your losses; May 13, 2024 deadline

      LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Anavex Life Sciences Corp. (NASDAQ:AVXL) investors that a lawsuit was filed on behalf of investors that purchased Anavex securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. Anavex is engaged in the research, production, and marketing of p

      5/1/24 6:31:25 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVXL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Donhauser Peter D.O. bought $10,319 worth of shares (2,835 units at $3.64), increasing direct ownership by 131% to 5,000 units (SEC Form 4)

      4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

      6/17/24 7:30:10 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Thomas Steffen bought $22,600 worth of shares (5,000 units at $4.52) (SEC Form 4)

      4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

      5/17/24 6:01:00 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVXL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Anavex downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Anavex from Overweight to Neutral and set a new price target of $11.00 from $16.00 previously

      12/6/22 9:27:26 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Berenberg initiated coverage on Anavex with a new price target

      Berenberg initiated coverage of Anavex with a rating of Buy and set a new price target of $40.00

      6/23/22 7:28:39 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Anavex Life Sciences with a new price target

      HC Wainwright & Co. reiterated coverage of Anavex Life Sciences with a rating of Buy and set a new price target of $42.00 from $39.00 previously

      2/2/22 6:36:27 AM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVXL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Anavex Life Sciences Corp.

      10-Q - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)

      5/13/25 4:31:17 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Anavex Life Sciences Corp.

      DEFA14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)

      4/25/25 4:35:45 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Anavex Life Sciences Corp.

      DEF 14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)

      4/25/25 4:31:01 PM ET
      $AVXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care